Latest news with #Divi'sLabs
&w=3840&q=100)
Business Standard
26-05-2025
- Business
- Business Standard
Divi's Labs share up 4%, hits record high on inking supply deal; details
Divi's Laboratories share price: Pharmaceutical giant Divi's Laboratories (Divi's Labs) shares were buzzing in trade on Monday, May 26, 2025, with the scrip rising up to 4.37 per cent to hit a record high of ₹6,764 per share. At 12:00 noon, Divi's Laboratories shares were trading 3.95 per cent higher at ₹6,737. In comparison, BSE Sensex was trading 0.57 per cent higher at 82,189.23 level. Catch Latest Stock Market Updates Today LIVE What led to Divi's Laboratories share price hitting 52-week high today? Divi's Laboratories share price rose after the company announced that it has inked a long-term manufacturing and supply agreement with a global pharmaceutical company. Under this deal, Divi's Laboratories will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. The pharmaceutical company also expects meaningful revenue contribution from this long-term agreement. Besides, the cost of capacity addition for manufacturing under this agreement is estimated to be ₹650-750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase-wise, according to the deal. Divi's Laboratories Q4 results The company's net profit jumped 23 per cent year-on-year (Y-o-Y) to ₹662 crore, as against ₹538 crore a year ago. Its revenue from operations increased 12 per cent annually to ₹2,585 crore, from ₹2,303 crore a year ago. Divi's Laboratories dividend The company's board recommended a final dividend of ₹30 per share of face value ₹2 each for FY25. The company has fixed July 25, 2025, as the record date for the purpose of the payment of dividend. ALSO READ | Ashok Leyland shares trade range-bound post Q4 results, declares 1:1 bonus About Divi's Laboratories Divi's Laboratories, established in 1990 and headquartered in Hyderabad, India, is a prominent global pharmaceutical company. Renowned for its strong focus on research and manufacturing, the company specializes in the production and export of active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals. With operations spanning 95 countries, Divi's Laboratories maintains a strong international footprint. Its diverse product portfolio includes generic APIs, custom-synthesised compounds, and nutraceutical ingredients. In addition to its core offerings, the company provides custom synthesis and contract manufacturing services, catering to major pharmaceutical companies at various stages of the drug development lifecycle—from clinical trials to commercial production.
&w=3840&q=100)
Business Standard
21-04-2025
- Business
- Business Standard
Divi's Labs jumps 4% after signing supply agreement with global pharma firm
Divi's Labs shares price: Shares of Divi's Laboratories jumped over 4 per cent to hit an intraday high ₹5,914 after the company signed a supply agreement with a global pharma company. According to the long-term agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. Divi's Labs said in an exchange filing that it expects meaningful revenue contribution from this long-term agreement. However, the company did not disclosed the identity of the partner. "The company is planning for capacity addition at its manufacturing facilities with an estimated investment between ₹650 crore to ₹700 crore, to be funded from internal accruals," the company said. At 10:10 AM on Monday, the stock was quoting at ₹5,855.50, up 3.81 per cent from Thursday, April 17 close of ₹5,640. In comparison, the benchmark NSE Nifty50 index was trading at 24,058.55, up 206.90 points or 0.87 per cent. The stock has fallen around 6 per cent from its 52-week high of ₹6,285.45 touched on December 3, 2024. The total market capitalisation of the company stood at ₹1.5 trillion. Divi's Labs Q3 flashback In December 2024 quarter (Q3 FY25), the company reported consolidated net profit of ₹589 crore, up 64 per cent from ₹358 crore in the corresponding quarter of previous fiscal. The company's revenue from operations stood at ₹2,319 crore, up 25 per cent compared to ₹1,855 crore in the year-ago period. Sequentially, the company's net profit increased 15 per cent. However, the revenue declined marginally by 0.80 per cent on a quarterly basis. About Divi's Laboratories Established in 1990, Divi's Laboratories is a supplier of generic APIs (Active pharmaceutical ingredients) and a custom manufacturer to Big Pharma. It is among the top API manufacturers in the world. It has two advanced manufacturing facilities in both Hyderabad and Vizag. The company has a portfolio of around 160 products around several therapeutic areas and a presence across more than 100 countries. The company has two subsidiaries Divis Laboratories (USA) Inc in the USA and Divi's Laboratories Europe AG in Switzerland.
